Ahmed Hamed Salem

Publication Activity (10 Years)

Years Active: 2016-2024
Publications (10 Years): 29

Top Topics

Multiple Myeloma

Chronic Lymphocytic Leukemia

Top Venues

Clinical and translational science

Hematological oncology

Clinical drug investigation

This page only lists publications with an associated author ORCID identifier.

Publications

Ahmed Hamed Salem, Rajeev M Menon
Clinical pharmacokinetics and pharmacodynamics of venetoclax, a selective B-cell lymphoma-2 inhibitor. Clinical and translational science 17 (5) (2024)
Ahmed Hamed Salem, Rajeev M Menon
Clinical pharmacokinetics and pharmacodynamics of venetoclax, a selective B-cell lymphoma-2 inhibitor. Clinical and translational science 17 (5) (2024)
Ahmed Hamed Salem, Rajeev M Menon
Clinical pharmacokinetics and pharmacodynamics of venetoclax, a selective B-cell lymphoma-2 inhibitor. Clinical and translational science 17 (5) (2024)
Meenakshi Hegde, Shoba A Navai, Christopher DeRenzo, Sujith K Joseph, Khaled Sanber, Mengfen Wu, Ahmed Z Gad, Katherine A Janeway, Matthew Campbell, Dolores Mullikin, Zeid Nawas, Catherine Robertson, Pretty R Mathew, Huimin Zhang, Birju Mehta, Raksha R Bhat, Angela Major, Ankita Shree, Claudia Gerken, Mamta Kalra, Rikhia Chakraborty, Sachin G Thakkar, Olga Dakhova, Vita S Salsman, Bambi Grilley, Natalia Lapteva, Adrian Gee, Gianpietro Dotti, Riyue Bao, Ahmed Hamed Salem, Nicholas Wang, Malcolm K Brenner, Helen E Heslop, Winfried S Wels, M John Hicks, Stephen Gottschalk, Nabil M Ahmed
Autologous HER2-specific CAR T cells after lymphodepletion for advanced sarcoma: a phase 1 trial. Nature cancer 5 (6) (2024)
Meenakshi Hegde, Shoba A Navai, Christopher DeRenzo, Sujith K Joseph, Khaled Sanber, Mengfen Wu, Ahmed Z Gad, Katherine A Janeway, Matthew Campbell, Dolores Mullikin, Zeid Nawas, Catherine Robertson, Pretty R Mathew, Huimin Zhang, Birju Mehta, Raksha R Bhat, Angela Major, Ankita Shree, Claudia Gerken, Mamta Kalra, Rikhia Chakraborty, Sachin G Thakkar, Olga Dakhova, Vita S Salsman, Bambi Grilley, Natalia Lapteva, Adrian Gee, Gianpietro Dotti, Riyue Bao, Ahmed Hamed Salem, Nicholas Wang, Malcolm K Brenner, Helen E Heslop, Winfried S Wels, M John Hicks, Stephen Gottschalk, Nabil M Ahmed
Autologous HER2-specific CAR T cells after lymphodepletion for advanced sarcoma: a phase 1 trial. Nature cancer 5 (6) (2024)
Meenakshi Hegde, Shoba A Navai, Christopher DeRenzo, Sujith K Joseph, Khaled Sanber, Mengfen Wu, Ahmed Z Gad, Katherine A Janeway, Matthew Campbell, Dolores Mullikin, Zeid Nawas, Catherine Robertson, Pretty R Mathew, Huimin Zhang, Birju Mehta, Raksha R Bhat, Angela Major, Ankita Shree, Claudia Gerken, Mamta Kalra, Rikhia Chakraborty, Sachin G Thakkar, Olga Dakhova, Vita S Salsman, Bambi Grilley, Natalia Lapteva, Adrian Gee, Gianpietro Dotti, Riyue Bao, Ahmed Hamed Salem, Nicholas Wang, Malcolm K Brenner, Helen E Heslop, Winfried S Wels, M John Hicks, Stephen Gottschalk, Nabil M Ahmed
Autologous HER2-specific CAR T cells after lymphodepletion for advanced sarcoma: a phase 1 trial. Nature cancer 5 (6) (2024)
Meenakshi Hegde, Shoba A Navai, Christopher DeRenzo, Sujith K Joseph, Khaled Sanber, Mengfen Wu, Ahmed Z Gad, Katherine A Janeway, Matthew Campbell, Dolores Mullikin, Zeid Nawas, Catherine Robertson, Pretty R Mathew, Huimin Zhang, Birju Mehta, Raksha R Bhat, Angela Major, Ankita Shree, Claudia Gerken, Mamta Kalra, Rikhia Chakraborty, Sachin G Thakkar, Olga Dakhova, Vita S Salsman, Bambi Grilley, Natalia Lapteva, Adrian Gee, Gianpietro Dotti, Riyue Bao, Ahmed Hamed Salem, Nicholas Wang, Malcolm K Brenner, Helen E Heslop, Winfried S Wels, M John Hicks, Stephen Gottschalk, Nabil M Ahmed
Autologous HER2-specific CAR T cells after lymphodepletion for advanced sarcoma: a phase 1 trial. Nature cancer (2024)
Ryota Kikuchi, Yuli Qian, Mohamed Badawi, John P Savaryn, Shashikanth Gannu, Ann Eldred, Shuai Hao, Ahmed Hamed Salem, Wei Liu, Cheri E Klein, Mohamed-Eslam F Mohamed
Coproporphyrin-I as a Selective OATP1B Biomarker Can Be Used to Delineate the Mechanisms of Complex Drug-Drug Interactions: Cedirogant Case Study. Clinical pharmacology and therapeutics (2024)
Behnam Noorani, Rajeev M Menon, Xin Chen, Kennan C Marsh, Weize Huang, Shelly Gupta, Edyta Dobkowska, Thomas C Marbury, Ahmed Hamed Salem
Venetoclax Pharmacokinetics in Participants with End-stage Renal Disease Undergoing Hemodialysis. British journal of clinical pharmacology (2023)
Sathej Gopalakrishnan, Rajeev Menon, Ahmed A Suleiman, Arnon P Kater, Stephan Stilgenbauer, John F Seymour, Brenda Chyla, Tong Lu, Su Young Kim, Andrew W Roberts, Jennifer A Woyach, Sven Mensing, Ahmed Hamed Salem
Relationship Between Venetoclax Exposure and Undetectable Minimal Residual Disease Rates in Relapsed/Refractory Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of Six Clinical Studies. HemaSphere 7 (12) (2023)
Mohamed Badawi, Sheryl Coppola, Doerthe Eckert, Sathej Gopalakrishnan, Benjamin Engelhardt, Eva Doelger, Weize Huang, Edyta Dobkowska, Shaji Kumar, Rajeev M Menon, Ahmed Hamed Salem
Venetoclax in biomarker-selected multiple myeloma patients: Impact of exposure on clinical efficacy and safety. Hematological oncology (2023)
Deanna Brackman, Doerthe Eckert, Rajeev Menon, Ahmed Hamed Salem, Jalaja Potluri, B Douglas Smith, Andrew H Wei, John Hayslip, Dale Miles, Sven Mensing, Sathej Gopalakrishnan, Jiuhong Zha
Venetoclax exposure-efficacy and exposure-safety relationships in patients with treatment-naïve acute myeloid leukemia who are ineligible for intensive chemotherapy. Hematological oncology 40 (2) (2022)
Dwaipayan Mukherjee, Deanna J Brackman, Ahmed A Suleiman, Jiuhong Zha, Rajeev M Menon, Ahmed Hamed Salem
Impact of Multiple Concomitant CYP3A Inhibitors on Venetoclax Pharmacokinetics: A PBPK and Population PK-Informed Analysis. Journal of clinical pharmacology (2022)
Mohamed Badawi, Xin Chen, Patrick Marroum, Ahmed A Suleiman, Sven Mensing, Anette Koenigsdorfer, Julia Teresa Schiele, Tammy Palenski, Divya Samineni, David Hoffman, Rajeev M Menon, Ahmed Hamed Salem
Bioavailability Evaluation of Venetoclax Lower-Strength Tablets and Oral Powder Formulations to Establish Interchangeability with the 100 mg Tablet. Clinical drug investigation 42 (8) (2022)
Matthew S Davids, Andrew W Roberts, Vaishalee P Kenkre, William G Wierda, Abhijeet Kumar, Thomas J Kipps, Michelle Boyer, Ahmed Hamed Salem, John C Pesko, Jennifer A Arzt, Margaret Mantas, Su Y Kim, John Francis Seymour
Long-term Follow-up of Patients with Relapsed or Refractory Non-Hodgkin Lymphoma Treated with Venetoclax in a Phase I, First-in-Human Study. Clinical cancer research : an official journal of the American Association for Cancer Research 27 (17) (2021)
Amr Alaarg, Rajeev Menon, David Rizzo, Yemin Liu, Jeffrey Bien, Tricia Elkinton, Timothy Grieme, Lutz R Asmus, Ahmed Hamed Salem
A microdosing framework for absolute bioavailability assessment of poorly soluble drugs: A case study on cold-labeled venetoclax, from chemistry to the clinic. Clinical and translational science (2021)
Ahmed Hamed Salem, Zhi-Fu Tao, Orlando F Bueno, Jie Chen, Shuang Chen, Rohinton Edalji, Steven W Elmore, Keith M Fournier, Kaid C Harper, Richard Hong, Gary J Jenkins, Jianguo Ji, Russell A Judge, John C Kalvass, Russell C Klix, Yi-Yin Ku, Joel D Leverson, Richard A Marks, Kennan C Marsh, Rajeev M Menon, Chang H Park, Darren C Phillips, Yu-Ming Pu, Saul H Rosenberg, Yeshwant D Sanzgiri, Ahmad Y Sheikh, Yi Shi, Deanne Stolarik, Ahmed A Suleiman, Xilu Wang, Geoff G Z Zhang, Nathaniel D Catron, Andrew J Souers
Expanding the Repertoire for "Large Small Molecules": Prodrug ABBV-167 Efficiently Converts to Venetoclax with Reduced Food Effect in Healthy Volunteers. Molecular cancer therapeutics 20 (6) (2021)
Akshanth R Polepally, Juki W Ng, Ahmed Hamed Salem, Matthew B Dufek, Apurvasena Parikh, David C Carter, Kent Kamradt, Nael M Mostafa, Mohamad Shebley
Assessment of Clinical Drug-Drug Interactions of Elagolix, a Gonadotropin-Releasing Hormone Receptor Antagonist. Journal of clinical pharmacology 60 (12) (2020)
Frederick J Kohlhapp, Dipica Haribhai, Rebecca Mathew, Ryan Duggan, Paul A Ellis, Rui Wang, Elisabeth A Lasater, Yan Shi, Nimita Dave, Jacob J Riehm, Valerie A Robinson, An D Do, Yijin Li, Christine J Orr, Deepak Sampath, Aparna Raval, Mark Merchant, Anahita Bhathena, Ahmed Hamed Salem, Keith M Hamel, Joel D Leverson, Cherrie Donawho, William N Pappano, Tamar Uziel
Venetoclax Increases Intratumoral Effector T Cells and Antitumor Efficacy in Combination with Immune Checkpoint Blockade. Cancer discovery 11 (1) (2020)
J Scott Lee, Andrew W Roberts, Dennis Juarez, Thanh-Trang T Vo, Shruti Bhatt, Lee-Or Herzog, Sharmila Mallya, Richard J Bellin, Suresh K Agarwal, Ahmed Hamed Salem, Tu Xu, Jia Jia, Lingxiao Li, John R Hanna, Matthew S Davids, Angela G Fleischman, Susan O'Brien, Lloyd T Lam, Joel D Leverson, Anthony Letai, Jonathan H Schatz, David A Fruman
Statins enhance efficacy of venetoclax in blood cancers. Science translational medicine 10 (445) (2019)
Nimita Dave, Sathej Gopalakrishnan, Sven Mensing, Ahmed Hamed Salem
Model-Informed Dosing of Venetoclax in Healthy Subjects: An Exposure-Response Analysis. Clinical and translational science 12 (6) (2019)
Rong Deng, Leonid Gibiansky, Tong Lu, Xiaobin Li, Dan Lu, Chunze Li, Sandhya Girish, Jue Wang, Michelle Boyer, Noopur Shankar, Kathryn Humphrey, Kevin J Freise, Ahmed Hamed Salem, John F Seymour, Arnon P Kater, Dale Miles
Exposure-response analysis of venetoclax in combination with rituximab in patients with relapsed or refractory chronic lymphocytic leukemia: pooled results from a phase 1b study and the phase 3 MURANO study. Leukemia & lymphoma 61 (1) (2019)
Suresh Agarwal, Sathej Gopalakrishnan, Sven Mensing, Jalaja Potluri, John Hayslip, Whitney Kirschbrown, Anna Friedel, Rajeev Menon, Ahmed Hamed Salem
Optimizing venetoclax dose in combination with low intensive therapies in elderly patients with newly diagnosed acute myeloid leukemia: An exposure-response analysis. Hematological oncology 37 (4) (2019)
Naveen Mangal, Ahmed Hamed Salem, Rajeev M Menon, Kevin J Freise
Use of depth of response to predict progression-free survival in relapsed or refractory multiple myeloma: Evaluation of results from 102 clinical trials. Hematological oncology (2018)
Suresh K Agarwal, Ahmed Hamed Salem, Alexey V Danilov, Beibei Hu, Soham Puvvada, Martin Gutierrez, David Chien, Lionel D Lewis, Shekman L Wong
Effect of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics of venetoclax, a BCL-2 inhibitor, in patients with non-Hodgkin lymphoma. British journal of clinical pharmacology 83 (4) (2017)
Apurvasena Parikh, Sathej Gopalakrishnan, Kevin J Freise, Maria E Verdugo, Rajeev M Menon, Sven Mensing, Ahmed Hamed Salem
Exposure-response evaluations of venetoclax efficacy and safety in patients with non-Hodgkin lymphoma. Leukemia & lymphoma 59 (4) (2017)
Tommy T Cheung, Ahmed Hamed Salem, Rajeev M Menon, Wijith P Munasinghe, Orlando F Bueno, Suresh K Agarwal
Pharmacokinetics of the BCL-2 Inhibitor Venetoclax in Healthy Chinese Subjects. Clinical pharmacology in drug development 7 (4) (2017)
Ahmed Hamed Salem, Beibei Hu, Kevin J Freise, Suresh K Agarwal, Dilraj S Sidhu, Shekman L Wong
Evaluation of the Pharmacokinetic Interaction between Venetoclax, a Selective BCL-2 Inhibitor, and Warfarin in Healthy Volunteers. Clinical drug investigation 37 (3) (2017)
Kevin J Freise, Martin Dunbar, Aksana K Jones, David Hoffman, Sari L Heitner Enschede, Shekman Wong, Ahmed Hamed Salem
Venetoclax does not prolong the QT interval in patients with hematological malignancies: an exposure-response analysis. Cancer chemotherapy and pharmacology 78 (4) (2016)